Showing 13,461 - 13,480 results of 48,899 for search '(( a ((mean decrease) OR (linear decrease)) ) OR ( a ((greatest decrease) OR (largest decrease)) ))', query time: 0.93s Refine Results
  1. 13461
  2. 13462
  3. 13463

    Determination of the main factors contributing to increases in medicine expenditures for the National Health Insurance Fund in Sudan by Mousnad, M. A.

    Published 2013
    “…To assess the main factors that contributed to the increase in medicine expenditure of the National Health Insurance Fund in Sudan in the period 2006–2010. A time-series decomposition analysis was adopted for pharmaceutical expenditure increases characterized by trends and seasonality (time-series data per quarter). …”
    Get full text
    Get full text
  4. 13464

    Role of RNA binding proteins and relative single-cell populations in modulating <i>SERPINA1</i> APA. by Lela Lackey (815515)

    Published 2021
    “…<p>A) Two-dimensional volcano plot of endogenous shRNA distal ratio in <i>SERPINA1</i> (y-axis) as a function of log<sub>2</sub> differential expression fold change (log<sub>2</sub>(DE<sub>FC</sub>)) in LTRC primary lung tissue from 376 COPD cases and 267 controls for the 224 corresponding RNA binding proteins. …”
  5. 13465
  6. 13466
  7. 13467
  8. 13468

    Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial by Vlado Perkovic (141532)

    Published 2020
    “…The primary outcome was time to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (3P-MACE), with a secondary outcome renal death, end-stage kidney disease, or sustained ≥40% decrease in eGFR from baseline. …”
  9. 13469
  10. 13470
  11. 13471
  12. 13472
  13. 13473

    Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts - Fig 1 by Ansar S. Zhalyalov (4233721)

    Published 2017
    “…<p>Pictures of fibrin clot growth in the absence of plasminogen activators (2 (A1), 10 (A2) and 20 (A3) minutes after the clotting onset) and clot growth and lysis in the presence of 30 nmol/L of TPA (2 (B1), 10 (B2) and 20 (B3) minutes after the clotting onset). …”
  14. 13474
  15. 13475

    Comparison of COCC. by Hazoor Ahmad (17508777)

    Published 2023
    “…As compared to state of the art, we achieve decreased sensation error in terms of small root-mean-square difference (70%, 61%, and 84% decrease in case of longitudinal acceleration, lateral acceleration, and yaw velocity, respectively) and improved coefficient of cross-correlation (3% and 1% increase in case of longitudinal and lateral acceleration, respectively).…”
  16. 13476

    Comparison of maximum angle. by Hazoor Ahmad (17508777)

    Published 2023
    “…As compared to state of the art, we achieve decreased sensation error in terms of small root-mean-square difference (70%, 61%, and 84% decrease in case of longitudinal acceleration, lateral acceleration, and yaw velocity, respectively) and improved coefficient of cross-correlation (3% and 1% increase in case of longitudinal and lateral acceleration, respectively).…”
  17. 13477

    Comparison of maximum displacement. by Hazoor Ahmad (17508777)

    Published 2023
    “…As compared to state of the art, we achieve decreased sensation error in terms of small root-mean-square difference (70%, 61%, and 84% decrease in case of longitudinal acceleration, lateral acceleration, and yaw velocity, respectively) and improved coefficient of cross-correlation (3% and 1% increase in case of longitudinal and lateral acceleration, respectively).…”
  18. 13478

    Comparison of RMSD. by Hazoor Ahmad (17508777)

    Published 2023
    “…As compared to state of the art, we achieve decreased sensation error in terms of small root-mean-square difference (70%, 61%, and 84% decrease in case of longitudinal acceleration, lateral acceleration, and yaw velocity, respectively) and improved coefficient of cross-correlation (3% and 1% increase in case of longitudinal and lateral acceleration, respectively).…”
  19. 13479
  20. 13480

    Inhibitory effects of FIPI or VU0155072-2 “NOPT” in mouse mammary tumors following xenotransplantation of human breast cancer cells. by Karen M. Henkels (3350273)

    Published 2016
    “…<p>(<b>A-C</b>) SCID mice were xenotransplanted with human MDA-MB-231 breast cancer cells following implantation of Alzet pumps containing 2 different PLD-small molecule inhibitors of activity: 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) or N- [2- (4- oxo- 1- phenyl- 1, 3, 8- triazaspiro[4, 5]dec- 8- yl)ethyl]- 2- naphthalenecarboxamide (VU0155072-2) [also referred to as “NOPT” [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0166553#pone.0166553.ref031" target="_blank">31</a>,<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0166553#pone.0166553.ref040" target="_blank">40</a>–<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0166553#pone.0166553.ref042" target="_blank">42</a>]]. …”